濮阳东方医院看男科病价格不高(濮阳东方医院妇科做人流手术) (今日更新中)

The skies over several US states and Ontario, Canada, lit up briefly on Wednesday as a presumed fireball streaked over the daytime sky.Despite the midday sun, the fireball was clearly visible in videos captured at the time of the event.According to the American Meteor Society, dozens of eyewitnesses reported seeing the fireball shortly after 12 p.m. ET. The reports were clustered around Lake Ontario, but the organization received reports from Michigan, Ohio, and even as far away as Maryland and Virginia.An eyewitness in Ohio reported to the American Meteor Society, “It was like a ball of fire with a tail...surreal to see in the daytime.”Another eyewitness in Ontario said, “Astonishing, amazing, still get goosebumps talking about it.”What caused the bright flash hasn’t been confirmed, but is presumed to be a meteor. Meteors are not uncommon events, as small rocks and objects enter the Earth’s atmosphere on a daily basis. Most of the time, the atmosphere causes these objects to burn up before reaching the ground. 1034

The US House of Representatives will vote on whether to legalize marijuana across the country in September. This would be the first time a chamber of Congress has ever voted on removing marijuana from the Controlled Substances Act.Cannabis was included as what is called a Schedule I drug under the Controlled Substances Act in 1970. Schedule I drugs are defined as having a high potential for abuse and no medical benefit. Other Schedule I drugs include heroin, LSD, ecstasy and peyote.On Friday, representatives were informed the MORE Act will come up for a vote in the September work period of the House.The MORE Act - Marijuana Opportunity Reinvestment and Expungement Act - will expunge some cannabis records and create grant opportunities for people who have been negatively impacted by the criminalization of marijuana in addition to removing it from its Schedule I classification, according to Politico.Marijuana is already legal in 11 states, despite the federal designation as a Schedule I drug.Senate Majority Leader Mitch McConnell is opposed to the act, and some say the odds of it passing the senate are very slim.Even if the MORE Act passes both chambers of Congress, it would not make sales of marijuana legal. Regulation of marijuana would be left to states to decide how to handle it. 1310

The White House has cut ties with a senior adviser to first lady Melania Trump after it was revealed the aide's firm was paid close to million to plan events around President Donald Trump's inauguration.The first lady's office said in a statement that it ended its contract with Stephanie Winston Wolkoff, who had been working as a special government employee."The Office of the First Lady severed the gratuitous services contract with Ms. Wolkoff. We thank her for her hard work and wish her all the best," said spokeswoman Stephanie Grisham.The New York Times first reported Wolkoff's departure.Inauguration committee tax documents revealed last week showed WIS Media Partners, a company based in Marina Del Ray, California, and founded by Wolkoff, received ,843,509 for "event production services."The roughly million the company received for its work on the inauguration was likely passed through to other vendors and event coordinators. The New York Times reported that Wolkoff personally received .62 million for her work.She told the Times on Monday that most of the million was paid to subcontractors, and that the .62 million was divided among 15 employees. Messages left by CNN with Wolkoff were not immediately returned.Last week, Grisham said Melania Trump "had no involvement" in planning the inauguration and had "no knowledge of how funds were spent."Trump and Wolkoff are longtime friends.  1438

The US House of Representatives passed a bill Wednesday to fund more security at schools, exactly one month after a gunman killed 17 people at a high school in Parkland, Florida, and as thousands of students take part in a national walkout in protest of gun violence.While the bill had bipartisan support, many Democrats were frustrated that it doesn't include any gun control measures."This is a pretense that we are doing something while assuring the NRA that we aren't doing anything," Rep. Steny Hoyer of Maryland, the second ranking Democrat in the House, told reporters Tuesday.The vote was 407-10. The bill attempts to curb school violence by providing more training for school officials and local law enforcement to respond to mental health crises, as well as, among other things, money to develop anonymous reporting systems for threats and deterrent measures like metal detectors and locks.Many Democratic lawmakers pressed Republican leaders to bring up gun control measures to expand background checks and ban assault weapons, but House GOP leaders continue to say they will wait to see what, if anything, the Senate can pass.In the Senate, the Judiciary Committee held a hearing on the Florida shooting and failures by the FBI and law enforcement to act on warning signs displayed by the gunman before the attack."In the wake of the Parkland attack, this committee has an obligation to find out what happened," said Senate Judiciary Committee Chairman Chuck Grassley, an Iowa Republican, in his opening remarks. "We must hold government to account for its failures, and make sure plans are in place to avoid future tragedies. And we must rally around consensus, evidenced-based solutions that will protect our nation's most valuable resource — its youth — from violent attacks."Both the hearing and the vote happened the same day students across the country are holding walkouts to commemorate the Parkland shooting anniversary and call for more action gun control measures. In Washington, global advocacy group Avaaz placed 7,000 pairs of shoes on the Capitol lawn to represent gun violence victims since the 2012 Sandy Hook Elementary School massacre. Protesters are demonstrating at the Capitol and in front of the White House on Wednesday.Both of Florida's senators -- Republican Marco Rubio and Democrat Bill Nelson -- testified at the hearing. The two men have also teamed up on legislation that would encourage states to adopt so-called red flag laws, which would give law enforcement the authority to seize guns from people who pose a threat to themselves or others.It's one of many gun control bills proposed by members on both sides of the aisle, but most efforts have largely stalled.President Donald Trump reiterated his support last weekend for a bill by Sen. John Cornyn of Texas, the No. 2 Republican in the Senate, and Democratic Sen. Chris Murphy of Connecticut that would encourage states and federal agencies to enter more data into the National Instant Criminal Background Check System, known as "Fix NICS."It was first introduced last fall after the Sutherland Springs, Texas, church shooting but it has seen renewed attention since last month's Florida shooting. While the bill currently has more than 60 cosponsors -- a normal indicator that it could avoid a filibuster -- many Democrats want to open up the legislation to amendments, and it's unclear how Republican leaders will proceed."I'm extremely interested in seeing Senator Cornyn's Fix NICS bill passed and a significant school safety bill passed," Senate Majority Leader Mitch McConnell told reporters on Tuesday. "The best way to get that done is still under discussion. But I'm anxious to pass both of them, and pass both of them soon."The witness list at the Senate Judiciary Committee hearing also included David L. Bowdich, the acting deputy director of the FBI, as well as Ryan Petty, whose daughter was killed in the Florida shooting, and Katherine Posada, a teacher at the school, Marjory Stoneman Douglas High School.And while there were no gun industry witnesses at the first hearing since the shooting, they loom large in the debate and play a critical role in lobbying members of Congress and rallying their supporters across the country during elections.The House bill, the STOP School Violence Act, aims to provide more training for school officials and local law enforcement to respond to mental health crises, as well as, among other things, money to develop anonymous reporting systems for threats and deterrents like metal detectors and locks.It does not include many of the components of a proposal unveiled by the White House -- most notably it does not include any provisions to arm teachers. House Republicans have largely ignored the President's plan, especially since he publicly declared that the major legislation the GOP-controlled chamber passed in December to loosen concealed carry rules was not something that could pass as part of broader gun legislation."This is about schools but it's not just about schools," Rubio told reporters Tuesday at a news conference about the Senate version of the bill. "When someone is determined that they're going to commit an act of violence, it could be in a school, it could be in a mall, it could be in a movie theater, it could be in an airport, it could be at a stadium. So what we're really focused on here more than anything else is identifying the people that are going to commit a violent act irrespective of where they're going to commit it and stopping them before they do it." 5558

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

来源：资阳报